Worth reading
61In focus
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Improvement
Direction inferred from the company’s description.Scale
1500
¥ millionWording
Conditional
How definitive the wording is.Revised forecast
Fiscal year ended December 2024 · Second quarter (interim period) and full yearPrevious forecast published 10 May 2024Net SalesInterim period8,350→8,882million
+6.4%
Net SalesFull year17,000→18,500million
+8.8%
Operating profitInterim period1,800→2,362million
+31.3%
Operating profitFull year3,650→4,900million
+34.2%
Ordinary incomeInterim period1,900→2,641million
+39.0%
Ordinary incomeFull year3,800→5,200million
+36.8%
Profit attributable to owners of the parentInterim period1,300→1,890million
+45.4%
Profit attributable to owners of the parentFull year2,650→3,600million
+35.8%
Net income per shareInterim period69.43→100.97yen
+45.4%
Net income per shareFull year141.52→192.26yen
+35.9%
The bar length represents the relative magnitude of change, based on the item that changed the most in this document. The percentage change shown by the dotted line is calculated from the two reported figures because the company did not provide the rate.
Reason for the revision
円安の進行、エレクトロニクス業界の関連分野の緩やかな回復、製品需要の堅調な推移により売上高が計画を上回った。利益面では、薬品需要の増加による生産効率向上、グローバル生産戦略による生産効率改善、販売費及び一般管理費が想定より少なく進捗したこと等により、前回予想を上回った。業績の進捗状況を踏まえ、薬品の需要予測と販売費及び一般管理費を見直した。
Previous-period resultsInterim period Net Sales 6,198 / Operating profit 838 / Ordinary income 1,003 / Interim net income attributable to owners of the parent 1,076 / Interim net income per share 56.79 / Full year Net Sales 14,020 / Operating profit 2,492 / Ordinary income 2,683 / Profit attributable to owners of the parent 2,304 / Net income per share 122.29
Consolidated / non-consolidatedConsolidated
| Item | Details |
|---|---|
| Net Sales | Interim period 8,350 / Full year 17,000 → Interim period 8,882 / Full year 18,500（Interim period 6.4 / Full year 8.8） |
| Operating profit | Interim period 1,800 / Full year 3,650 → Interim period 2,362 / Full year 4,900（Interim period 31.3 / Full year 34.2） |
| Ordinary income | Interim period 1,900 / Full year 3,800 → Interim period 2,641 / Full year 5,200（Interim period 39 / Full year 36.8） |
| Profit attributable to owners of the parent | Interim period 1,300 / Full year 2,650 → Interim period 1,890 / Full year 3,600（Interim period 45.4 / Full year 35.8） |
| Net income per share | Interim period 69.43 / Full year 141.52 → Interim period 100.97 / Full year 192.26 |
| Fiscal Period Covered | Fiscal year ended December 2024 |
| Period Covered | Second quarter (interim period) and full year |
| Publication date of previous forecast | 10 May 2024 |
| Previous-period results | Interim period Net Sales 6,198 / Operating profit 838 / Ordinary income 1,003 / Interim net income attributable to owners of the parent 1,076 / Interim net income per share 56.79 / Full year Net Sales 14,020 / Operating profit 2,492 / Ordinary income 2,683 / Profit attributable to owners of the parent 2,304 / Net income per share 122.29 |
| Reason for the revision | 円安の進行、エレクトロニクス業界の関連分野の緩やかな回復、製品需要の堅調な推移により売上高が計画を上回った。利益面では、薬品需要の増加による生産効率向上、グローバル生産戦略による生産効率改善、販売費及び一般管理費が想定より少なく進捗したこと等により、前回予想を上回った。業績の進捗状況を踏まえ、薬品の需要予測と販売費及び一般管理費を見直した。 |
| Consolidated / non-consolidated | Consolidated |
Items this document does not state (2)
Details and amount of extraordinary lossDividend forecast revision
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.円安の進行、エレクトロニクス業界の関連分野の緩やかな回復、製品需要の堅調な推移により売上高が予想を上回った。利益面では、薬品需要の増加による生産効率向上、グローバル生産戦略による生産効率改善、販売費及び一般管理費が想定より少なく進捗したことが寄与した。これらを踏まえ、薬品の需要予測と販売費及び一般管理費を見直した。
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.